- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Topical for acne vulgaris
Ortho Dermatologics has announced that RETIN-A MICRO® (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals.
Ortho Dermatologics has announced that RETIN-A MICRO® (tretinoin) gel microsphere 0.06% is now available commercially to healthcare professionals. Studies have shown that the microsponge delivery system technology helps to control the release of tretinoin and improves photostability, even when used in conjunction with benzoyl peroxide, and a pump delivery system allows for controlled dispensing and consistent dosing.
The U.S. Food and Drug Administration (FDA) approved the Supplemental New Drug Application (sNDA) for RETIN-A MICRO® (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgaris on October 24, 2017.
FOR MORE INFORMATION: https://www.ortho-dermatologics.com
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
